Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

2(40.0%)

Phase 4

2(40.0%)

N/A

1(20.0%)

5Total

Phase 3(2)

Phase 4(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06520826Phase 3Active Not Recruiting

Vafseo Outcomes In-Center Experience

Role: lead

NCT05085275Phase 3Completed

Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease

Role: lead

NCT06691672Not ApplicableCompleted

Feasibility Study of Dialysis Clinic Semi-Autonomous Ultrasound Scanning Using the Vexev Ultrasound Imaging System for Arteriovenous Fistula Mapping Examinations. The CANSCAN Trial.

Role: collaborator

NCT05951192Phase 4Completed

A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease

Role: lead

NCT04922645Phase 4Completed

Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants

Role: lead

All 5 trials loaded